Stock Analysis

Why Biogen Inc. (NASDAQ:BIIB) Is An Attractive Investment To Consider

NasdaqGS:BIIB
Source: Shutterstock

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Biogen Inc. (NASDAQ:BIIB) due to its excellent fundamentals in more than one area. BIIB is a company with a an impressive history of performance, trading at a discount. In the following section, I expand a bit more on these key aspects. For those interested in understanding where the figures come from and want to see the analysis, take a look at the report on Biogen here.

Advertisement

Solid track record and good value

In the previous year, BIIB has ramped up its bottom line by 57%, with its latest earnings level surpassing its average level over the last five years. The strong earnings growth is reflected in impressive double-digit 34% return to shareholders, which is an notable feat for the company. BIIB is currently trading below its true value, which means the market is undervaluing the company's expected cash flow going forward. This mispricing gives investors the opportunity to buy into the stock at a cheap price compared to the value they will be receiving, should analysts' consensus forecast growth be correct. Also, relative to the rest of its peers with similar levels of earnings, BIIB's share price is trading below the group's average. This supports the theory that BIIB is potentially underpriced.

NasdaqGS:BIIB Income Statement, May 22nd 2019
NasdaqGS:BIIB Income Statement, May 22nd 2019

Next Steps:

For Biogen, I've put together three important aspects you should look at:

  1. Future Outlook: What are well-informed industry analysts predicting for BIIB’s future growth? Take a look at our free research report of analyst consensus for BIIB’s outlook.
  2. Financial Health: Are BIIB’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of BIIB? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqGS:BIIB

Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

Flawless balance sheet and undervalued.

Advertisement